The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, including blood and bone marrow cancers, leukemia, and myeloma.
August 21st 2025
Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.
Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML
CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.
Read More
EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma
July 29th 2025Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.
Read More
EHA 2025: No Added Toxicity Observed With Bleximenib Plus Venetoclax and Azacitidine in AML
July 22nd 2025Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.
Read More
FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns
July 18th 2025The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.
Read More
NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.
Read More